This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Sandi Kwee, Queen's Medical Centre
ClinicalTrials.gov Identifier:
NCT00928174
First received: June 24, 2009
Last updated: October 13, 2015
Last verified: October 2015
History of Changes
Results First Received: October 1, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Condition: Prostate Cancer
Intervention: Drug: IV administration of fluorine-18 fluorocholine followed by PET/CT imaging

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Single Arm

Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.

IV administration of fluorine-18 methylcholine followed by PET/CT imaging: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.

Participant Flow:   Overall Study
    Single Arm
STARTED   27 
COMPLETED   22 [1] 
NOT COMPLETED   5 
[1] 3 withdrawn before start of participation



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Single Arm

Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.

IV administration of fluorine-18 methylcholine followed by PET/CT imaging: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.

Baseline Measures
   Single Arm 
Overall Participants Analyzed 
[Units: Participants]
 		 27 
Age, Customized [1] 
[Units: Participants]
 		 
<40   0 
40-49 years   0 
50-59 years   1 
60-69 years   9 
70-79 years   4 
80-89 years   13 
[1] Age (10-year groupings)
Gender 
[Units: Participants]
 		 
Female   0 
Male   27 
Race (NIH/OMB) 
[Units: Participants]
 		 
American Indian or Alaska Native   0 
Asian   13 
Native Hawaiian or Other Pacific Islander   4 
Black or African American   0 
White   9 
More than one race   0 
Unknown or Not Reported   1 
Region of Enrollment 
[Units: Participants]
 		 
United States   27 


  Outcome Measures

1.  Primary:   Prostate Specific Antigen (PSA) Outcome Correspondence to Imaging Results With Fluorine-18 Fluorocholine PET/CT   [ Time Frame: Concurrent with PET Procedure ]
  Show Outcome Measure 1


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Sandi Kwee, Principal Investigator
Organization: The Queen's Medical Center
phone: 808-691-5466
e-mail: skwee@queens.org



Responsible Party: Sandi Kwee, Queen's Medical Centre
ClinicalTrials.gov Identifier: NCT00928174     History of Changes
Other Study ID Numbers: RA-2009-009
R21CA139687 ( US NIH Grant/Contract Award Number )
Study First Received: June 24, 2009
Results First Received: October 1, 2014
Last Updated: October 13, 2015